Mundipharma Signs an Exclusive Commercialization and Distribution Agreement with Biosolution in South Korea

Mundipharma Signs an Exclusive Commercialization and Distribution Agreement with Biosolution in South Korea

Shots:

  • Mundipharma to get exclusive rights to market and distribute Biosolution’s CartiLife in South Korea. In May 2016, the companies signed commercialization agreement for allogeneic keratinocyte cell therapy product, KeraHeal-Allo and is the second agreement signed presently
  • The focus of the agreement is to include Biosolution’s CartiLife in the Mundipharma’s portfolio of orthopedic care
  • CartiLife is a fourth-generation autologous cartilage-derived chondrocyte cell therapy targeted to treat cartilage defects (ICRS grade 3 or 4) involved in reduction of host-immune rejection due to its autologous nature with restoration of hyaline cartilage causing less invasion surgery

Click here to read full press release/ article | Ref: PRNewswire | Image: Evaluate